![](https://3dprint.com/wp-content/uploads/2019/09/allevi-300x169.png)
The Allevi Liver dECM promises the fabrication of liver tissue that has a more representative physiological function. The product uses a combination of a type I collagen Allevi bioink for patterning as well as Xylyx Bio’s highly desired liver-specific TissueSpec® ECM to enhance specialized biological response.
Xylyx Bio products for cell culture are obtained from porcine or human tissue sources and processed to various formats, enabling cell culture models that are significantly more predictive of physiology. Their 3D TissueSpec® ECM hydrogels and scaffolds provide support to cell culture models, facilitating the acceleration of drug discovery, development and tissue regeneration.
“We are thrilled to partner with Allevi and share our expertise in tissue-specific ECM,” stated Andrea Nye, Chief Executive Officer at Xylyx Bio. “Recognizing the importance of the native cellular microenvironment, Xylyx Bio harnesses the body’s innate biology in the form of tissue-specific extracellular matrix. By sourcing extracellular matrix from native organs and tissues, Xylyx produces tissue-specific substrates that comprise both the mechanical properties and complex ratios of ECM components specific and unique to each tissue and organ type.”
Founded in 2014, Allevi claims that its “mission is to provide users the ability to design, engineer, and manufacture 3D tissue.” To deliver important building blocks and provide users with the best experience possible to drive new scientific discoveries, Allevi is hopeful that the new dECM bioink will provide scientists a revolutionary approach that allows scientists to print 3D tissue structures with biochemical and mechanical features inherent in human physiology.
[Images: Allevi and Xylyx Bio]
Xylyx Bio’s Co-founder and Chief Strategy Officer, John O’Neil, added that a “deeper understanding of the comprehensive nature of tissues and cells and their interaction with the cellular microenvironment – that is, the extracellular matrix – holds great promise to lead to a paradigm shift in 3D bioprinting, allowing researchers to study physiologic activity of cells in vitro towards a better understanding of disease and development of more effective drugs and treatments.”
Subscribe to Our Email Newsletter
Stay up-to-date on all the latest news from the 3D printing industry and receive information and offers from third party vendors.
You May Also Like
Regular, Medium, and Large Format 3D Printing Explained
At Additive Manufacturing (AM) Research and on 3DPrint.com, we use the terms regular, medium, and large format to segment the 3D printing market. We developed these terms to help bring...
Global Materials Group Acquires Canadian Hardfacing Metal Firm, Boosting 3D Printing Portfolio
Consolidation in the additive manufacturing (AM) service bureau segment continues to take place. The latest news sees international provider Wall Colmonoy acquire Indurate Alloys Ltd., a Canadian supplier of hardfacing...
Beyond Chuck Hull’s Legacy: the Unsung Heroes Who Paved the Way for 3D Printing
Next month, we will celebrate a huge anniversary. 40 years ago, on August 8, 1984, Charles Hull filed a patent application for stereolithography: the first additive manufacturing technique in history,...
3DPOD Episode 207: 3D Printed Electronics with Richard Neill, CEO of Advanced Printed Electronic Solutions
Rich Neill is refreshingly clear and direct about 3D printed electronics. His previous venture allowed him to start Advanced Printed Electronic Solutions with his own money, making him beholden to...